TY - JOUR
T1 - B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection
T2 - A European Hematology Association Survey (EPICOVIDEHA)
AU - Infante, Maria Stefania
AU - Salmanton-García, Jon
AU - Fernández-Cruz, Ana
AU - Marchesi, Francesco
AU - Jaksic, Ozren
AU - Weinbergerová, Barbora
AU - Besson, Caroline
AU - Duarte, Rafael F.
AU - Itri, Federico
AU - Valković, Toni
AU - Szotkovski, Tomáš
AU - Busca, Alessandro
AU - Guidetti, Anna
AU - Glenthøj, Andreas
AU - Collins, Graham P.
AU - Bonuomo, Valentina
AU - Sili, Uluhan
AU - Seval, Guldane Cengiz
AU - Machado, Marina
AU - Cordoba, Raul
AU - Blennow, Ola
AU - Abu-Zeinah, Ghaith
AU - Lamure, Sylvain
AU - Kulasekararaj, Austin
AU - Falces-Romero, Iker
AU - Cattaneo, Chiara
AU - van Doesum, Jaap
AU - Piukovics, Klára
AU - Omrani, Ali S.
AU - Magliano, Gabriele
AU - Ledoux, Marie-Pierre
AU - de Ramon, Cristina
AU - Cabirta, Alba
AU - Verga, Luisa
AU - López-García, Alberto
AU - da Silva, Maria Gomes
AU - Stojanoski, Zlate
AU - Meers, Stef
AU - Lahmer, Tobias
AU - Martín-Pérez, Sonia
AU - Dávila-Vals, Julio
AU - van Praet, Jens
AU - Samarkos, Michail
AU - Bilgin, Yavuz M.
AU - Karlsson, Linda Katharina
AU - Batinić, Josip
AU - Nordlander, Anna
AU - Schönlein, Martin
AU - Hoenigl, Martin
AU - Ráčil, Zdeněk
AU - Mladenović, Miloš
AU - Hanakova, Michaela
AU - Zambrotta, Giovanni Paolo Maria
AU - de Jonge, Nick
AU - Adžić-Vukičević, Tatjana
AU - Nunes-Rodrigues, Raquel
AU - Prezioso, Lucia
AU - Navrátil, Milan
AU - Marchetti, Monia
AU - Cuccaro, Annarosa
AU - Calbacho, Maria
AU - Giordano, Antonio
AU - Cornely, Oliver A.
AU - Hernández-Rivas, José-Ángel
AU - Pagano, Livio
N1 - Publisher Copyright: Copyright © 2022 Infante, Salmanton-García, Fernández-Cruz, Marchesi, Jaksic, Weinbergerová, Besson, Duarte, Itri, Valković, Szotkovski, Busca, Guidetti, Glenthøj, Collins, Bonuomo, Sili, Seval, Machado, Cordoba, Blennow, Abu-Zeinah, Lamure, Kulasekararaj, Falces-Romero, Cattaneo, Van Doesum, Piukovics, Omrani, Magliano, Ledoux, de Ramon, Cabirta, Verga, López-García, Da Silva, Stojanoski, Meers, Lahmer, Martín-Pérez, Dávila-Vals, Van Praet, Samarkos, Bilgin, Karlsson, Batinić, Nordlander, Schönlein, Hoenigl, Ráčil, Mladenović, Hanakova, Zambrotta, De Jonge, Adžić-Vukičević, Nunes-Rodrigues, Prezioso, Navrátil, Marchetti, Cuccaro, Calbacho, Giordano, Cornely, Hernández-Rivas and Pagano.
PY - 2022/10/3
Y1 - 2022/10/3
N2 - Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
AB - Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
KW - SARS-CoV-2
KW - chronic lymphocytic leukemia (CLL)
KW - immune system COVID19
KW - infection risk
KW - lymphoproliferative diseases (LPD)
KW - non-Hodgkin lymphoma (NHL)
KW - targeted drugs
UR - http://www.scopus.com/inward/record.url?scp=85140595614&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fonc.2022.992137
DO - https://doi.org/10.3389/fonc.2022.992137
M3 - Article
C2 - 36276116
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 992137
ER -